494 related articles for article (PubMed ID: 33798642)
1. The past, present, and future of breast cancer models for nanomedicine development.
Boix-Montesinos P; Soriano-Teruel PM; Armiñán A; Orzáez M; Vicent MJ
Adv Drug Deliv Rev; 2021 Jun; 173():306-330. PubMed ID: 33798642
[TBL] [Abstract][Full Text] [Related]
2. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages.
Yu W; Hu C; Gao H
Adv Drug Deliv Rev; 2021 Nov; 178():113909. PubMed ID: 34352354
[TBL] [Abstract][Full Text] [Related]
3. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
4. Current understandings and clinical translation of nanomedicines for breast cancer therapy.
Jiang Y; Jiang Z; Wang M; Ma L
Adv Drug Deliv Rev; 2022 Jan; 180():114034. PubMed ID: 34736986
[TBL] [Abstract][Full Text] [Related]
5. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
6. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
9. Smart cancer nanomedicine.
van der Meel R; Sulheim E; Shi Y; Kiessling F; Mulder WJM; Lammers T
Nat Nanotechnol; 2019 Nov; 14(11):1007-1017. PubMed ID: 31695150
[TBL] [Abstract][Full Text] [Related]
10. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
11. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
12. Nanomedicine Tumor Targeting.
Lammers T
Adv Mater; 2024 Jun; 36(26):e2312169. PubMed ID: 38361435
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
14. Nanotargeted agents: an emerging therapeutic strategy for breast cancer.
Du M; Ouyang Y; Meng F; Ma Q; Liu H; Zhuang Y; Pang M; Cai T; Cai Y
Nanomedicine (Lond); 2019 Jul; 14(13):1771-1786. PubMed ID: 31298065
[TBL] [Abstract][Full Text] [Related]
15. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
16. Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine.
Pearce AK; O'Reilly RK
Bioconjug Chem; 2019 Sep; 30(9):2300-2311. PubMed ID: 31441642
[TBL] [Abstract][Full Text] [Related]
17. Microbiota and cancer: In vitro and in vivo models to evaluate nanomedicines.
Ladaycia A; Loretz B; Passirani C; Lehr CM; Lepeltier E
Adv Drug Deliv Rev; 2021 Mar; 170():44-70. PubMed ID: 33388279
[TBL] [Abstract][Full Text] [Related]
18. In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles.
Abreu TR; Biscaia M; Gonçalves N; Fonseca NA; Moreira JN
Adv Exp Med Biol; 2021; 1295():271-299. PubMed ID: 33543464
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive review on immuno-nanomedicine for breast cancer therapy: Technical challenges and troubleshooting measures.
Saravanakumar K; Anbazhagan S; Pujani Usliyanage J; Vishven Naveen K; Wijesinghe U; Xiaowen H; Vishnu Priya V; Thiripuranathar G; Wang MH
Int Immunopharmacol; 2022 Feb; 103():108433. PubMed ID: 34922248
[TBL] [Abstract][Full Text] [Related]
20. Nanomedicine in treatment of breast cancer - A challenge to conventional therapy.
Afzal M; Ameeduzzafar ; Alharbi KS; Alruwaili NK; Al-Abassi FA; Al-Malki AAL; Kazmi I; Kumar V; Kamal MA; Nadeem MS; Aslam M; Anwar F
Semin Cancer Biol; 2021 Feb; 69():279-292. PubMed ID: 31870940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
